



SUVEN LIFE SCIENCES LTD

Regd. Off: SDE Serene Chambers, Road No. 5, Banjara Hills, Hyderabad - 500 034

Rs. In Lakhs

STATEMENT OF UN-AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & 6 MONTHS PERIOD ENDED 30th Sept ' 2019

PART - I		STANDALONE					
Sl. No.	PARTICULARS	For the Quarter Ended			For the 6 months period ended		For the year Ended
		30/09/2019	30/06/2019	30/09/2018	30/09/2019	30/09/2018	31/03/2019
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
1	Income						
	Revenue from operations	27,431.49	19,898.63	8,952.18	47,330.12	28,118.40	66,350.44
	Other Income	558.52	300.67	658.63	859.19	1,471.40	2,422.93
	Total income	27,990.01	20,199.30	9,610.81	48,189.31	29,589.80	68,773.37
2	Expenses						
	a) Cost of materials consumed	6,047.63	5,866.31	4,102.39	11,913.94	7,961.69	20,413.82
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	3,057.82	(1,732.14)	(3,525.10)	1,325.68	(929.28)	(3,061.41)
	d) Employee benefits expense	1,684.58	1,875.41	1,398.33	3,559.99	3,113.15	6,347.79
	e) Finance costs	185.41	130.75	59.09	316.16	165.88	376.31
	f) Depreciation and amortisation expense	559.08	555.03	556.05	1,114.11	1,106.86	2,214.05
	g) Manufacturing Exps	2,762.42	2,534.68	2,493.06	5,297.10	4,778.56	9,982.32
	h) R & D Exps	1,466.43	1,310.14	1,238.73	2,776.57	2,837.60	6,027.60
	i) Other Expenses	1,359.16	1,040.96	803.29	2,400.12	2,092.10	4,286.59
	Total expenses	17,122.53	11,581.14	7,125.84	28,703.67	21,126.56	46,587.07
3	Profit before exceptional items & Tax (1-2)	10,867.48	8,618.16	2,484.97	19,485.64	8,463.24	22,186.30
4	Exceptional Items	-	-	-	-	-	-
5	Profit before Tax (3-4)	10,867.48	8,618.16	2,484.97	19,485.64	8,463.24	22,186.30
6	Tax Expenses						
	a) Current tax	3,646.51	3,483.61	513.83	7,130.12	1,762.97	4,604.23
	b) Deferred tax	(10.94)	(583.22)	170.17	(594.16)	1,015.09	2,575.78
7	Net Profit/ (Loss) for the period/year(5-6)	7,231.91	5,717.77	1,800.97	12,949.68	5,685.18	15,006.29
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(5.29)	(5.29)	(10.59)	(10.58)	(21.17)	(21.16)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	1.85	1.85	3.67	3.70	7.33	7.39
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(3.44)	(3.44)	(6.92)	(6.88)	(13.84)	(13.77)
9	Total Comprehensive Income for the period (7+8)	7,228.47	5,714.33	1,794.05	12,942.80	5,671.34	14,992.52
10	Paid-up equity share capital	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity	111,030.80	103,802.33	91,068.49	111,030.80	91,068.49	98,088.00
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :						
	a) Basic	5.68	4.49	1.41	10.17	4.47	11.79
	b) Diluted	5.68	4.49	1.41	10.17	4.47	11.79
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	

SEGMENT WISE REVENUE, RESULTS AND TOTAL ASSETS AND LIABILITIES							Rs. In Lakhs
PART - II		STANDALONE					
PARTICULARS	For the Quarter Ended			For the 6 months period ended		For the year Ended	
	30/09/2019	30/06/2019	30/09/2018	30/09/2019	30/09/2018	31/03/2019	
	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited	
1	SEGMENT REVENUE :-						
	a) Manufacturing (CRAMS)	26,709.93	19,616.35	8,087.96	46,326.28	26,112.18	61,362.91
	b) Services (DDDSS)	721.56	282.28	864.22	1,003.84	2,006.22	4,987.53
	c) Research & Development	-	-	-	-	-	-
	TOTAL	27,431.49	19,898.63	8,952.18	47,330.12	28,118.40	66,350.44
	Less Inter segment Revenue	-	-	-	-	-	-
	Net Sales from Operations	27,431.49	19,898.63	8,952.18	47,330.12	28,118.40	66,350.44
2	SEGMENT RESULTS :-						
	Profit/(Loss) before tax and interest:						
	a) Manufacturing (CRAMS)	12,541.33	10,587.58	3,252.05	23,128.91	10,338.79	26,594.91
	b) Services (DDDSS)	100.53	60.20	440.55	160.73	1,201.70	2,558.00
	c) Research & Development	(1,466.42)	(1,310.15)	(1,238.71)	(2,776.57)	(2,837.59)	(6,027.60)
	TOTAL	11,175.44	9,337.63	2,453.89	20,513.07	8,702.90	23,125.31
Less:	i) Interest	69.85	46.41	62.29	116.26	98.26	199.02
	ii) Other Un-allocable expenditure/(Income), net	238.11	673.06	(93.37)	911.17	141.40	739.99
	Total Profit Before Tax	10,867.48	8,618.16	2,484.97	19,485.64	8,463.24	22,186.30
3	SEGMENT ASSETS :						
	a) Manufacturing (CRAMS)	74,332.00	72,577.41	57,618.63	74,332.00	57,618.63	69,666.60
	b) Services (DDDSS)	5,675.23	5,629.15	3,767.31	5,675.23	3,767.31	5,687.52
	c) Research & Development	2,889.12	2,918.73	3,028.20	2,889.12	3,028.20	3,022.45
	d) Un allocated	56,698.57	43,436.44	44,219.74	56,698.57	44,219.74	39,125.31
	TOTAL	139,594.92	124,561.73	108,633.88	139,594.92	108,633.88	117,501.88
	SEGMENT LIABILITIES :						
	a) Manufacturing (CRAMS)	17,849.98	11,100.58	9,282.73	17,849.98	9,282.73	9,189.76
	b) Services (DDDSS)	648.76	273.05	473.46	648.76	473.46	641.72
	c) Research & Development	2,136.52	1,610.78	1,669.94	2,136.52	1,669.94	1,592.07
	d) Un allocated	1,362.26	1,197.17	949.14	1,362.26	949.14	829.03
	TOTAL	21,997.52	14,181.58	12,375.27	21,997.52	12,375.27	12,252.58

		Rs. In Lakhs					
PART - I		CONSOLIDATED					
Sl. No.	PARTICULARS	For the Quarter Ended			For the 6 months period ended		For the year Ended
		30/09/2019	30/06/2019	30/09/2018	30/09/2019	30/09/2018	31/03/2019
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
1	Income						
	Revenue from operations	27,431.49	19,898.63	8,952.18	47,330.12	28,118.40	66,350.44
	Other Income	558.52	300.67	658.62	859.19	1,471.40	2,422.93
	Total income	27,990.01	20,199.30	9,610.80	48,189.31	29,589.80	68,773.37
2	Expenses						
	a) Cost of materials consumed	6,047.63	5,866.31	4,102.40	11,913.94	7,961.69	20,413.82
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress	3,057.82	(1,732.14)	(3,525.09)	1,325.68	(929.27)	(3,061.41)
	d) Employee benefits expense	1,723.93	1,942.44	1,464.88	3,666.37	3,240.86	6,612.45
	e) Finance costs	229.10	168.72	59.37	397.82	166.42	377.38
	f) Depreciation and amortisation	559.08	555.03	556.05	1,114.11	1,106.86	2,214.05
	g) Manufacturing Exps	2,762.42	2,534.68	2,493.06	5,297.10	4,778.56	9,982.32
	h) R & D Exps	2,279.38	4,285.71	2,573.37	6,565.09	5,349.17	11,985.07
	i) Other Expenses	1,364.88	1,057.26	816.15	2,422.14	2,148.43	4,375.37
	Total expenses	18,024.24	14,678.01	8,540.19	32,702.25	23,822.72	52,899.05
3	Profit before exceptional items , Tax (1-2)	9,965.77	5,521.29	1,070.61	15,487.06	5,767.08	15,874.32
4	Exceptional Items	-	-	-	-	-	-
5	Profit before Tax (3-4)	9,965.77	5,521.29	1,070.61	15,487.06	5,767.08	15,874.32
6	Tax Expenses						
	a) Current tax	3,645.51	3,483.61	513.83	7,130.12	1,762.97	4,604.23
	b) Deferred tax	(10.94)	(583.22)	170.18	(594.16)	1,015.09	2,575.78
7	Net Profit/ (Loss) for the period/year(7-8)	6,331.20	2,620.90	386.60	8,951.10	2,989.02	8,694.31
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(5.29)	(5.29)	(10.59)	(10.58)	(21.17)	(21.16)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	1.85	1.85	3.67	3.70	7.33	7.39
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(3.44)	(3.44)	(6.92)	(6.88)	(13.84)	(13.77)
9	Total Comprehensive Income for the period (9 + 10)	6,327.76	2,617.46	379.68	8,944.22	2,975.18	8,680.54
10	Paid-up equity share capital Face Value of the Share	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00
11	Other Equity	91,008.57	84,178.15	78,400.98	91,008.57	78,400.98	81,826.56
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :						
	a) Basic	4.97	2.06	0.30	7.03	2.35	6.83
	b) Diluted	4.97	2.06	0.30	7.03	2.35	6.83
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	

PART - II		CONSOLIDATED					Rs. In Lakhs
PARTICULARS	For the Quarter Ended			For the 6 months period ended		For the year Ended	
	30/09/2019	30/06/2019	30/09/2018	30/09/2019	30/09/2018	31/03/2019	
	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited	
1	SEGMENT REVENUE :-						
	a) Manufacturing (CRAMS)	26,709.93	19,616.35	8,087.96	46,326.28	26,112.18	61,362.91
	b) Services (DDDSS)	721.56	282.28	864.22	1,003.84	2,006.22	4,987.53
	c) Research & Development	-	-	-	-	-	-
	TOTAL	27,431.49	19,898.63	8,952.18	47,330.12	28,118.40	66,350.44
	Less Inter segment Revenue	-	-	-	-	-	-
	Net Sales from Operations	27,431.49	19,898.63	8,952.18	47,330.12	28,118.40	66,350.44
2	SEGMENT RESULTS :-						
	Profit/(Loss) before tax and interest:						
	a) Manufacturing (CRAMS)	12,518.68	10,587.57	3,185.49	23,106.25	10,211.08	26,330.25
	b) Services (DDDSS)	100.53	60.20	439.12	160.73	1,197.68	2,551.33
	c) Research & Development	(2,197.21)	(4,367.88)	(2,573.37)	(6,565.09)	(5,349.16)	(11,985.07)
	TOTAL	10,422.00	6,279.89	1,051.24	16,701.89	6,059.60	16,896.51
Less:	i) Interest	113.14	84.05	62.29	197.19	98.26	199.02
	ii) Other Un-allocable expenditure/(Income), net	343.09	674.55	(81.66)	1,017.64	194.26	823.17
	Total Profit Before Tax	9,965.77	5,521.29	1,070.61	15,487.06	5,767.08	15,874.32
3	SEGMENT ASSETS :						
	a) Manufacturing (CRAMS)	73,686.97	71,575.12	57,203.42	73,686.97	57,203.42	69,668.49
	b) Services (DDDSS)	5,651.55	5,604.44	3,745.49	5,651.55	3,745.49	5,687.52
	c) Research & Development	3,587.69	4,055.30	3,501.11	3,587.69	3,501.11	3,022.45
	d) Un allocated	40,778.22	28,605.45	32,706.55	40,778.22	32,706.55	25,510.28
	TOTAL	123,704.43	109,840.31	97,156.57	123,704.43	97,156.57	103,888.74
	SEGMENT LIABILITIES :						
	a) Manufacturing (CRAMS)	18,665.47	8,798.99	9,092.14	18,665.47	9,092.14	9,912.30
	b) Services (DDDSS)	677.73	216.43	462.31	677.73	462.31	688.83
	c) Research & Development	5,277.36	9,118.52	3,058.61	5,277.36	3,058.61	3,388.76
	d) Un allocated	1,508.70	950.40	952.42	1,508.70	952.42	910.98
	TOTAL	26,129.26	19,084.34	13,565.48	26,129.26	13,565.48	14,900.87

1) The above results were reviewed by Audit Committee of the Board and approved by the Board of Directors' at their Meeting held on 14th Nov 2019 and the same has been reviewed by the Statutory Auditors.

2) The Company is in the process of evaluating the impact of newly introduced Sec.115BAA of the Taxation Laws (Amendments) Ordinance , 2019.

3) The acquisition of Assets and Liabilities in RISING PHARMA HOLDINGS, Inc., under the US Bankruptcy Code are still in process. Hence, the company did not consider RISING PHARMA HOLDINGS, Inc. for consolidation.

4) The corresponding previous period figures have been regrouped / reclassified where ever necessary.

For SUVEN LIFE SCIENCES LTD

VENKAT JASTI
Chairman & CEO
DIN: 00278028

Place : Hyderabad
Date : 14th Nov ' 2019



SUVEN LIFE SCIENCES LTD

Registered Office: 8-2-334, SDE Serene Chambers, 6th Floor, Road No. 5, Avenue 7, Banjara Hills, 500 034, Telangana, India.

CIN: L24110TG1989PLC009713

Tel: 91 40 2354 1142/ 3311/ 3315 **Fax:** 91 40 2354 1152 **email:** investorservices@suvan.com **website:** www.suvan.com

EXTRACT OF UN-AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th SEPT ' 2019

Rs. In Lakhs

Sl No.	Particulars	STANDALONE			CONSOLIDATED		
		30/09/2019	30/06/2019	30/09/2018	30/09/2019	30/06/2019	30/09/2018
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited
1	Total income from operations	27431.49	19898.63	8952.18	27431.49	19898.63	8952.18
2	Net profit for the period (before tax , exceptional and/or extraordinary items)	10867.48	8618.16	2484.97	9965.77	5521.29	1070.61
3	Net profit for the period before tax (after exceptional and/or extraordinary items)	10867.48	8618.16	2484.97	9965.77	5521.29	1070.61
4	Net profit for the period After tax (after exceptional and/or extraordinary items)	7231.91	5717.77	1800.97	6331.20	2620.90	386.60
5	Total comprehensive income for the period [comprising profit for the period (after tax) and other comprehensive income (after tax)]	7228.47	5714.33	1794.05	6327.76	2617.46	379.68
6	Equity share capital	1272.82	1272.82	1272.82	1272.82	1272.82	1272.82
7	Other Equity (Excluding Revaluation Reserve) as shown in the audited balance sheet.	98088.00			81826.56		
8	Earnings Per Share (Of Rs.1.00/- each)						
	1. Basic :	5.68	4.49	1.41	4.97	2.06	0.30
	2. Diluted:	5.68	4.49	1.41	4.97	2.06	0.30
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	-

Notes

1) The above is an extract of the detailed format of Quarterly/ Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the websites of the stock exchanges(s) and the listed entity. (www.bseindia.com and www.nseindia.com) and company's website www.suvan.com .

2) The Company is in the process of evaluating the impact of newly introduced Sec.115BAA of the Taxation Laws (Amendments) Ordinance , 2019.

3) The acquisition of Assets and Liabilities in RISING PHARMA HOLDINGS, Inc., under the US Bankruptcy Code are still in process. Hence, the company did not consider RISING PHARMA HOLDINGS, Inc. for consolidation.

For SUVEN LIFE SCIENCES LTD

VENKAT JASTI

Chairman & CEO

DIN: 00278028

Place : Hyderabad

Date: 14th NOV, 2019



SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

Statement of Assets & Liabilities

Rs.in Lakhs

Particulars	Standalone as at		Consolidated as at	
	30/09/2019	31/03/2019	30/09/2019	31/03/2019
A ASSETS				
1 Non-current assets				
(a) Property, Plant and Equipment	28,166.58	29,056.22	28,166.58	29,056.22
(b) Capital Work-in-Progress	13,800.40	11,108.68	13,800.40	11,108.68
(c) Other Intangible Assets	251.45	268.50	251.45	268.50
(d) Financial Assets				
I. Investments	40,664.43	13,644.38	24,682.06	7.05
II. Loans	7.34	7.22	7.34	7.22
III. Other Financial Assets	447.48	437.42	449.43	439.31
(e) Deferred tax assets (net)	-	-	-	-
(f) Other non current assets	1,565.09	679.94	1,565.09	679.94
Total Non-Current assets	84,902.77	55,202.36	68,922.35	41,566.92
2 Current assets				
(a) Inventories	15,231.36	15,709.83	15,231.36	15,709.83
(b) Financial Assets				
I. Investments	9,501.10	22,998.92	9,501.10	22,998.92
II. Trade Receivables	16,274.85	15,014.63	16,274.85	15,014.63
III. Cash and Cash equivalents	5,534.36	1,090.74	5,641.92	1,113.04
IV. Bank balances otherthan (III) above	247.52	245.14	247.52	245.14
V. Loans	33.18	11.47	15.55	11.47
VI. Other Financial assets	0.28	0.28	0.28	0.28
(c) Current Tax asset(net)	-	408.50	-	408.50
(d) Other current assets	7,869.50	6,820.01	7,869.50	6,820.01
Total Current assets	54,692.15	62,299.52	54,782.08	62,321.82
TOTAL - ASSETS	139,594.92	117,501.88	123,704.43	103,888.74
B EQUITY AND LIABILITIES				
1 EQUITY				
(a) Equity Share Capital	1,272.82	1,272.82	1,272.82	1,272.82
(b) Other Equity	111,030.80	98,088.00	91,008.57	81,826.56
Equity attributable to owners of the company	112,303.62	99,360.82	92,281.39	83,099.38
2 LIABILITIES				
(a) Financial Liabilities				
I. Borrowings	195.21	177.53	195.21	177.53
(b) Provisions	743.16	743.16	743.16	743.16
(c) Deferred tax Liabilities (net)	4,294.24	4,892.10	4,294.24	4,892.10
(d) Other non current liabilities	61.17	75.69	61.17	75.70
Total non-current liabilities	5,293.78	5,888.48	5,293.78	5,888.49
Current liabilities				
(a) Financial Liabilities				
I. Borrowings	8,487.90	3,529.24	12,013.90	3,530.24
II. Trade payables				
a) To Micro & Small Enterprises	755.71	73.22	755.71	73.22
b) Other than Micro & Small Enterprises	4,150.15	5,992.86	4,150.15	5,992.86
III. Other Financial Liabilities	2,098.45	1,837.06	2,704.19	4,484.35
(b) Current Tax liabilities (Net)	5,749.20	-	5,749.20	-
(c) Other Current liabilities	397.08	591.18	397.08	591.18
(d) Provision Employee benefits	359.03	229.02	359.03	229.02
Sub-total - Current liabilities	21,997.52	12,252.58	26,129.26	14,900.87
Total Liabilities	27,291.30	18,141.06	31,423.04	20,789.36
TOTAL - EQUITY AND LIABILITIES	139,594.92	117,501.88	123,704.43	103,888.74

For Suven Life Sciences Ltd

Place : Hyderabad

Date: 14th Nov, 2019

Venkat Jasti
Chairman & CEO